Table 2.
Factors associated with mortality in HIV/HTLV-1 co-infected and HIV-infected patients.
| Characteristics | Crude HR | 95% CI | p | Adjusted HR | 95% CI | p |
|---|---|---|---|---|---|---|
| Age at entry | 1.0 | 0.97–1.06 | 0.5 | |||
| Sex | ||||||
| Female | Reference | Reference | ||||
| Male | 1.2 | 0.47–3.21 | 0.7 | 0.2 | 0.02–1.96 | 0.2 |
| Marital status | ||||||
| Single | Reference | Reference | ||||
| Married/Cohabitant | 1.2 | 0.40–3.78 | 0.7 | 0.5 | 0.05–4.31 | 0.5 |
| Separated/Divorced/Widowed | 0.6 | 0.12–3.02 | 0.5 | 0.2 | 0.01–3.60 | 0.3 |
| Not specified | 5.6 | 1.89–16.84 | 0.002 | 3.3 | 8.54 × 10−20–1.25 × 1020 | 1.0 |
| Sexual orientation | ||||||
| Heterosexual | Reference | |||||
| Homosexual | 1.7 | 0.60–4.78 | 0.3 | |||
| Bisexual | 0.3 | 0.04–2.62 | 0.3 | |||
| Birthplace | ||||||
| Coastal region: Lima | Reference | |||||
| Rest of coastal region | 0.6 | 0.12–2.94 | 0.5 | |||
| Andean region | 0.5 | 0.16–1.57 | 0.2 | |||
| Amazon region | 1.2 | 0.16–9.51 | 0.8 | |||
| Level of education | ||||||
| None/Primary education | Reference | Reference | ||||
| Secondary education | 0.9 | 0.18–4.14 | 0.9 | 0.9 | 0.06–14.44 | 1.0 |
| Higher education | 1.2 | 0.23–6.46 | 0.8 | 2.1 | 0.12–39.88 | 0.6 |
| Not specified | 5.4 | 1.08–27.16 | 0.04 | 0.8 | 1.76 × 10−20–3.38 × 1019 | 1.0 |
| Employment status | ||||||
| Unemployed | Reference | |||||
| Employed | 0.9 | 0.37–2.28 | 0.9 | |||
| Associated retroviral infection | ||||||
| HIV | Reference | Reference | ||||
| HIV/HTLV-1 | 6.8 | 2.7–17.0 | <0.001 | 11.75 | 1.55–89.00 | 0.02 |
| Hepatitis B virus infection | ||||||
| No | Reference | |||||
| Yes | 1.2 | 0.3–5.7 | 0.8 | |||
| Sexually transmitted diseases * | ||||||
| No | Reference | |||||
| Yes | 0.6 | 0.2–1.6 | 0.3 | |||
| Herpes zoster disease | ||||||
| No | Reference | |||||
| Yes | 1.4 | 0.5–3.6 | 0.5 | |||
| Tuberculosis † | ||||||
| No | Reference | Reference | ||||
| Yes | 1.1 | 0.5–2.8 | 0.8 | 0.30 | 0.03–3.03 | 0.3 |
| Prophylaxis for OIs | ||||||
| No | Reference | |||||
| Yes | 0.6 | 0.2–1.9 | 0.4 | |||
| Use of ART | ||||||
| No | Reference | Reference | ||||
| Yes | 0.07 | 0.0–0.2 | <0.001 | 0.03 | 0.003–0.25 | 0.001 |
| Initial HIV stage | ||||||
| 1 | Reference | Reference | ||||
| 2 | 0.2 | 0.03–1.3 | 0.1 | 0.03 | 0.0009–0.95 | 0.05 |
| 3 | 0.4 | 0.06–2.5 | 0.3 | 0.03 | 0.0008–1.22 | 0.06 |
| 4 | 0.4 | 0.1–1.7 | 0.2 | 0.06 | 0.004–1.20 | 0.07 |
| Not specified | 2.0 | 0.5–8.6 | 0.3 | 0.61 | 0.015–24.53 | 0.8 |
| Initial HIV viral load ^ | ||||||
| Undetectable | Reference | Reference | ||||
| Detectable | 0.7 | 0.1–5.6 | 0.7 | 0.1 | 0.004–1.33 | 0.1 |
| HIV viral load at last visit | ||||||
| Undetectable | Reference | |||||
| Detectable | 4.4 | 1.5–13.2 | 0.008 | |||
| Initial CD4 cell count (cells/mm3) | ||||||
| <200 | Reference | |||||
| 200–500 | 0.7 | 0.2–2.5 | 0.6 | |||
| >500 | 5.1 × 10−16 | 0– | 1.00 | |||
| CD4 cell count at last visit (cells/mm3) | ||||||
| <200 | Reference | |||||
| 200–500 | 0.2 | 0.07–0.8 | 0.02 | |||
| >500 | 0.1 | 0.02–0.3 | <0.001 |
* Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, and Haemophilus ducreyi infections, herpes and genital warts, pediculosis pubis, and inguinal buboes. † Pulmonary and/or extrapulmonary tuberculosis infection. ^ WHO clinical staging of HIV/AIDS for adults and adolescents with confirmed HIV infection.